Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of November 25, 2024 • 7:31 PM ET

Date/Time Source News Release
11/15/2024 06:30 AM EST ACCESSWIRE NanoViricides, Inc. Has Filed its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID
10/22/2024 06:30 AM EDT ACCESSWIRE NanoViricides President Dr. Diwan to Present at the PODD Conference
10/15/2024 06:30 AM EDT ACCESSWIRE NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology
10/08/2024 06:30 AM EDT ACCESSWIRE NanoViricides to Present at the Global AMR Summit 2024 Tomorrow
09/30/2024 06:30 AM EDT ACCESSWIRE NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID
09/26/2024 06:30 AM EDT ACCESSWIRE NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including "Trojan Horse" Drugs
08/26/2024 07:30 AM EDT ACCESSWIRE MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX
08/19/2024 06:30 AM EDT ACCESSWIRE NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 -?A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections
08/08/2024 06:30 AM EDT ACCESSWIRE NanoViricides Provides an Update on Its Clinical Program and Strategy - NV-387 Could be As Revolutionary as Antibiotics
08/02/2024 07:00 AM EDT Newsfile Can Nanotechnology offer Better Solutions for COVID, RSV and other Viruses?
Page

Additional News

As of November 25, 2024 • 7:31 PM ET

Date/Time Source News Release
11/15/2024 08:30 AM EST InvestorBrandNetwork InvestorNewsBreaks - NanoViricides (NYSE American: NNVC) Reports Financial Progress and Advances Towards Key Phase II Clinical Trials
11/04/2024 08:30 AM EST InvestorBrandNetwork InvestorNewsBreaks - NanoViricides (NYSE American: NNVC) Highlights Broad-Spectrum Antiviral Advancements at Spartan Capital Investors Conference
10/22/2024 08:30 AM EDT InvestorBrandNetwork InvestorNewsBreaks - NanoViricides (NYSE American: NNVC) to Present Breakthrough Antiviral Platform and Drug Delivery Advances at PODD Conference
10/15/2024 08:30 AM EDT InvestorBrandNetwork InvestorNewsBreaks - NanoViricides (NYSE American: NNVC) CEO Featured in Latest Episode of PODD Podcast
10/08/2024 08:30 AM EDT InvestorBrandNetwork InvestorNewsBreaks - NanoViricides Inc. (NYSE American: NNVC) to Discuss Its 'Trojan Horse' Platform Technology at Upcoming Global AMR Summit
09/30/2024 08:30 AM EDT InvestorBrandNetwork InvestorNewsBreaks - NanoViricides Inc. (NYSE American: NNVC) Announces Filing of Fiscal 2024 Form 10-K
09/26/2024 08:30 AM EDT InvestorBrandNetwork InvestorNewsBreaks - NanoViricides Inc. (NYSE American: NNVC) Announces Execution of MoU Agreement with TheraCour Pharma
08/25/2024 08:01 AM EDT SeekingAlpha Earnings week ahead: NVIDIA, CrowdStrike, Salesforce, Lululemon and more
08/22/2024 08:30 AM EDT InvestorBrandNetwork InvestorNewsBreaks - NanoViricides (NYSE American: NNVC) Reports 'Extremely Significant Results in HV-387 Animal Study Treating RSV
08/06/2024 08:45 AM EDT Financial News Media Rapid Advancements of Innovative Antiviral - COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market
Page